Improving outcomes in intensified processing via optimization of the cell line development workflow
Biotechnology Progress · 2025
DOI: 10.1002/btpr.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2025. Verfasst von Vincent Balassi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Expression Systems and Novel Biopharmaceutical Materials, MilliporeSigma, Saint Louis, Missouri, USA. Hauptthemen laut MEDLINE: Batch Cell Culture Techniques, Cell Culture Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
As the industry continues to explore the benefits of continuous and intensified manufacturing, it is important to assure that the cell line development (CLD) workflows in practice today are well suited to generate clones that meet the unique challenges associated with these processes. Most cell lines used in intensified processes are currently developed using traditional fed‐batch CLD workflows followed by adaptation of these cell lines to perfusion processes. This method maybe suboptimal as fed‐batch CLD workflows select clones which produce high volumetric titers irrespective of cell growth rate and specific productivity (qP). Although sufficient for fed‐batch processes, performance of cells derived from this traditional CLD workflow may not be maintained in perfusion processes, where an intricate balance of performance parameters is needed. Until now, a thorough investigation into the effect of the CLD workflow on top clone performance in perfusion processes has not been conducted. Here, we show how the CLD workflow impacts cell performance in both fed‐batch and perfusion processes, emphasizing the advantages of adopting a perfusion‐specific CLD workflow which includes the use of medium specially designed for expansion and production in a perfusion setting, scale‐down models which more accurately simulate perfusion process, and the adoption of perfusion‐specific cell line selection criteria. Together, this results in the development of more efficient cell lines, fit for continuous and intensified processing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Expression Systems and Novel Biopharmaceutical Materials, MilliporeSigma, Saint Louis, Missouri, USA.
- Cell Culture Media and Process Development, MilliporeSigma, Saint Louis, Missouri, USA.
ORCID-Profile: David Razafsky
Zitieren
APA
Balassi, V., Otto, M., Kretzmer, C., Petersen, A., McLaurin, C., Mahadevan, J., Gustin, J., Borgschulte, T., & Razafsky, D. (2025). Improving outcomes in intensified processing via optimization of the cell line development workflow. Biotechnology Progress. https://doi.org/10.1002/btpr.70003
Vancouver
Balassi V, Otto M, Kretzmer C, Petersen A, McLaurin C, Mahadevan J, et al. Improving outcomes in intensified processing via optimization of the cell line development workflow. Biotechnology Progress. 2025. doi:10.1002/btpr.70003
BibTeX
@article{Balassi2025,
author = {Balassi, Vincent and Otto, Mary and Kretzmer, Corey and Petersen, Amber and McLaurin, Channing and Mahadevan, Jana and Gustin, Jason and Borgschulte, Trissa and Razafsky, David},
title = {Improving outcomes in intensified processing via optimization of the cell line development workflow},
journal = {Biotechnology Progress},
year = {2025},
doi = {10.1002/btpr.70003}
}
EUVIMED